LAS VEGAS, NV January 9, 2019 — Johnson & Johnson Innovation, JLABS and Janssen Research & Development, LLC announced today at the Baby Tech Summit at the Annual Consumer Electronics Show (CES) in Las Vegas, Nevada that San Francisco-based Bloomlife, a digital health company, has been selected as the awardee in the First 1000 Days Quickfire Challenge. The Challenge was designed to identify innovators with game-changing ideas for health technologies aimed at addressing the prevention and interception of childhood disease and disorders at the earliest stages of life. Kate Merton, head of Johnson & Johnson Innovation, JLABS in New York, made the announcement as part of a panel discussion at CES’ Baby Tech Summit titled, “Innovation in the First 1000 Days of Life: Driving Health & Well-Being for Babies (and Parents too).”
Bloomlife shared their vision to design the future of prenatal care to improve the health of moms and babies. CEO Eric Dy explains, “Through the most advanced combination of technology, medical expertise, and data science, we are bringing long overdue innovation to better understand pregnancy and its complications to improve birth outcomes for every mom and child.”
As the awardee in the First 1000 Days Quickfire Challenge, Bloomlife will receive $250,000 in grant funding to further advance its research in prenatal care, as well as mentoring from experts at Johnson & Johnson Innovation.
The first 1000 days of life sets a trajectory for health and a susceptibility to diseases that may occur either in the childhood and adult years. As the overall approach to healthcare transitions away from treating chronic disease after it manifests and moves towards preventing disease before it begins, the First 1000 Days QuickFire Challenge was launched in August 2018 to support innovations with the potential to better detect disease risks and that aim to provide support during the crucial first years of life.
The QuickFire Challenges are managed by Johnson & Johnson Innovation, JLABS, a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world.
For more information about the QuickFire Challenge, please visit: https://jlabs.jnjinnovation.com/quickfire-challenges.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation | JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com or follow @JNJinnovation.
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation | JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS.
Janssen Research & Development, LLC
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com . Follow us at @JanssenGlobal.
 Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: physiology or pathophysiology? Physiol Rev. 2014;94:1027-76.